(The Hill) — A new poll from the health policy nonprofit KFF found that one in eight adults say they’ve taken a GLP-1 agonist ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University ...

Lexaria's DehydraTECH-processed Rybelsus ® capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide ... Blood samples were taken multiple times during the first ...

Novo Nordisk’s stock value surged by over 8% following the drug’s presentation at an investor meeting on March 7, 2024.. The surging interest in a new class of medications known as GLP-1 ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug ... both adults and children. Vaxchora has been available in the US since ...

Thus, semaglutide’s appetite-suppressing effect makes it a useful drug for weight loss and management when used in conjunction with diet and exercise. Obesity in adults ... US are currently on a ...

The maker of a weight loss drug has asked regulators to allow them to expand the use of the medication down to the age of six. It comes as Liraglutide, a drug approved to treat obesity in adults and ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study shows. Liraglutide lowered body ...

A new class of insulin taken once a week could be just as effective for managing blood sugar in people with type 1 and type 2 ...